Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9057 in heart failure with volume overload
NCT06506994Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-9057 in heart failure (HF) (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Adverse Events at 14 days. Started Aug 2024; status: completed.
02
Drugs
HRS-9057
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06506994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506994.